IHH Healthcare (“IHH” or the “Group”), a world-leading integrated healthcare provider, has launched a transformative SGD5 million Research Grant & Innovation Sandbox programme to accelerate clinical research and innovation across its global network.
Disbursed over five years, the fund empowers IHH clinicians and employees to pursue impactful clinical research and pilot ground-up, innovative ideas that address critical health issues, driving advancements that improve patient experiences and outcomes. Depending on the strength of proposals and the interest level, the SGD5 million fund has the potential to grow further.
The first grant call in March this year focused on oncology and chronic diseases, two of the most critical fronts in our fight to improve global health.Out of 55 submissions, the Grant Governance Committee, comprising senior management and domain experts from across IHH, shortlisted seven Research Grant projects and eight Innovation Sandbox applications.
Under the Clinical Research track, each project is expected to be completed within one year – or up to a maximum of two years for complex cases – with findings and outcomes published as part of the wider healthcare literature on oncology and chronic diseases.The projects under the Innovation Sandbox track will prioritise ideas that demonstrate clear impact such as scalability across IHH markets, cost savings, improved patient outcomes and better patient experience.
The Group will open its next call for submissions in September this year, continuing its commitment to
empowering its people to shape the future of healthcare from within.
ABOUT IHH HEALTHCARE (“IHH”)
A world-leading integrated healthcare provider, IHH believes that making a difference starts with our aspiration to Care. For Good. Our team of more than 70,000 people commit to deliver greater good to our patients, people, the public and planet, as we live our purpose each day to touch lives and transform care. Through our portfolio of trusted brands – Acibadem, Mount Elizabeth, Prince Court, Island, Gleneagles, Fortis, Pantai and Parkway – we offer our patients comprehensive and personalised care ranging from primary to quaternary, and even ancillary services such as laboratory, diagnostics, imaging and rehabilitation.
With a clear focus on clinical excellence and innovation, we continue to raise the bar in healthcare in our key markets of Malaysia, Singapore, Türkiye, India, Greater China (including Hong Kong) and beyond. In partnership with our stakeholders, we will co-create a sustainable future for all as we work towards our vision to become the world’s most trusted healthcare services network.
